Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$29.32 - $35.99 $232,067 - $284,860
7,915 New
7,915 $252,000
Q1 2022

May 16, 2022

BUY
$53.73 - $82.16 $5,373 - $8,216
100 Added 1.85%
5,515 $316,000
Q4 2021

Feb 16, 2022

BUY
$68.02 - $99.06 $368,328 - $536,409
5,415 New
5,415 $432,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.78B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Kraematon Investment Advisors, Inc Portfolio

Follow Kraematon Investment Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kraematon Investment Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Kraematon Investment Advisors, Inc with notifications on news.